大剂量低频率重组人促红细胞生成素治疗肾性贫血临床观察

目的]观察大剂量低频率重组人促红细胞生成素(rhEPO)治疗肾性贫血的临床疗效及安全性.方法]对60例确诊为慢性肾衰竭合并肾性贫血的维持性血透患者,随机分为大剂量低频率rhEPO治疗组与小剂量高频率rhEPO对照组,治疗组应用10000U rhEPO每周1次皮下注射,对照组应用3000U rhEPO每周3次皮下注射,分别观察治疗前及用药后4周、8周及12周患者血红蛋白(Hb)、红细胞压积(Hct)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)的变化以及药物不良反应.结果]治疗组与对照组治疗12周后患者Hb、Hct、SF、TSAT均较治疗前有升高( P <0.01),且治疗组治疗4、8周后患者Hb、Hct水平升高更明显,贫血伴随症状得到明显纠正,与对照组比较有统计学意义( P <0.05).结论]大剂量低频率rhEPO能快速改善肾性贫血患者贫血情况、不良反应低、安全性良好.

Clinical Study of Large Dose and Low Frequency of Erythropoietin for the Treatment of Patients with Renal Anemia

Objective] To observe the clinical efficacy and safety of large dose and low frequency of recombinant human erythropoi- etin（rhEPO） for the treatment of renal anemia. Methods] Sixty maintenance hemodialysis patients diagnosed as chronic renal failure and renal anemia were randomly divided into treatment group with large dose and low frequency of rhEPO and control group with low dose and high frequency of rhEPO. The treatment group received subcutaneous injection with 10000U rhEPO once a week. The control group received subcutaneous injection with 3000U rhEPO 3 times a week. The changes of hemoglobin（Hb）, hematocrit（Hct）, serum ferritin（SF） and transferrin saturation（TSAT ） and adverse drug reaction were observed before and 4 weeks, 8 weeks and 12 weeks af- ter treatment. Results] Compared with before treatment, the levels of Hb, Her, SF and TSAT in treatment group and control group 12 weeks after treatment increased（ P 〈0. 01）. The levels of Hb and Hct in treatment group increased more obviously, and the concomitant symptoms of anemia were obviously relieved 4 weeks and 8 weeks after treatment, and there was significant difference between treatment group and control group（ P 〈0.05）. Conclusion] Large close and low frequency of rhEPO can rapidly improve anemia of patients with renal anemia, and has low adverse reaction and good safety.